Is eribulin treatment prognostic factor in patients with metastatic breast cancer treated with this drug? Retrospective analysis of a multicentre study


Oruc Z., Kaplan M. A., Geredeli C., Sari N. Y., Ozaslan E., Aytekin A., ...Daha Fazla

JOURNAL OF BUON, cilt.25, sa.2, ss.641-647, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 25 Sayı: 2
  • Basım Tarihi: 2020
  • Dergi Adı: JOURNAL OF BUON
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.641-647
  • Anahtar Kelimeler: metastatic breast cancer, eribulin, chemotherapy, prognostic factors, breast cancer, SURVIVAL, EFFICACY, THERAPY, WOMEN, ANTHRACYCLINE, MONOTHERAPY, MESYLATE, SAFETY
  • Marmara Üniversitesi Adresli: Evet

Özet

Purpose: This study aimed to analyze prognostic factors for survival and the reliability and the effectiveness of eribulin therapy in metastatic breast cancer (MBC) patients.